“South Africa’s Department of Health has announced a 2.88% increase in medicine prices across the private healthcare sector, marking the second extraordinary adjustment in 2026. The move responds to rising input costs, supply chain disruptions, and geopolitical tensions, aiming to sustain medicine availability while keeping prices predictable for patients and medical schemes.”
On October 1, 2026, South Africa’s Department of Health implemented a 2.88% increase in medicine prices under the Single Exit Price (SEP) framework. This decision, unusual in its timing as SEP adjustments typically occur once annually, reflects the government’s response to mounting economic and geopolitical pressures affecting the pharmaceutical sector.
Background: The SEP System
The Single Exit Price (SEP) system was introduced to eliminate price disparities across pharmacies, hospitals, and doctors. Under SEP, manufacturers set one regulated national price for medicines, ensuring uniformity and transparency. This framework has been crucial in preventing exploitative pricing practices and maintaining affordability in the private healthcare sector.
Why the Increase Now?
- January 2026 Adjustment: The first SEP increase this year was 1.47%, significantly lower than the 5.25% adjustment in 2025. Industry leaders argued this was insufficient to absorb rising costs.
- Cost Pressures: Input costs have surged by 30–40%, driven by the rand’s depreciation, the Gulf oil crisis, and disruptions around the Strait of Hormuz. These factors increased the cost of importing active pharmaceutical ingredients and transporting medicines.
- Job Losses: Approximately 2,500 pharmaceutical jobs were lost in the 18 months leading up to August 2026, underscoring the sector’s vulnerability.
Government’s Position
Department of Health spokesperson Foster Mohale emphasized that the adjustment was designed to provide temporary relief to manufacturers while maintaining affordability for patients. The government acknowledged the delicate balance between supply chain sustainability and consumer protection.
Impact on Patients and Medical Schemes
- Patients: Medicine prices in the private sector will rise, though the actual rand increase depends on each medicine’s existing SEP.
- Medical Schemes: Most schemes had budgeted for contribution increases of 3.2–3.3%, meaning the adjustment falls within expected ranges.
- Affordability Protections: The SEP framework ensures patients are shielded from arbitrary price hikes, with increases capped at the regulated percentage.
Industry Reaction
Pharmaceutical industry body Pharmisa welcomed the adjustment but noted it may still be insufficient. Chairperson Stavros Nicolaou highlighted that shortages were already emerging earlier this year due to inadequate pricing adjustments. The Pharmaceutical Task Group had requested an additional 1.73 percentage points in April, reflecting the severity of cost pressures.
Broader Economic Context
South Africa’s pharmaceutical sector is deeply intertwined with global supply chains.
- Geopolitical Tensions: Conflicts and disruptions in oil-producing regions have raised transportation costs.
- Currency Depreciation: The weakening rand has amplified import costs, particularly for raw materials.
- Domestic Inflation: While the effective full-year increase is closer to 2.19%, this remains below general inflation, suggesting the government’s cautious approach.
Patient Advocacy Concerns
Advocacy groups have expressed concern that even modest increases could disproportionately affect low-income patients reliant on private healthcare. While the SEP system prevents excessive variation, affordability remains a pressing issue, particularly for chronic medication users.
Conclusion
The 2.88% medicine price hike represents a critical intervention by South Africa’s Department of Health to stabilize the pharmaceutical sector amid global and domestic challenges. While the adjustment provides temporary relief for manufacturers, the long-term sustainability of medicine affordability will depend on continued government-industry collaboration, currency stabilization, and supply chain resilience.
